Group items tagged

A group of 21 community pharmacies in the Midlands and Yorkshire will have a new name - Pickfords Pharmacy. The group has been created by combining three independent pharmacy businesses which traded as Mr Pickford's, McGills Pharmacy and D&R Sharp. All pharmacies in the new group will be rebranded over the coming months, with a series of launch events planned by local teams. Speaking after the unveiling of the first branch to receive new signage in Hexthorpe Doncaster, Mimi Lau, Pickfords Pharmacy's chief operating officer, said: "This is a turning point for the group, with all our pharmacies operating under one name with a consistent, contemporary brand. "Initial reaction has been fantastic and very soon the name Pickfords Pharmacy will be widely recognised for the great service we deliver to customers and patients every day." Speaking of the consolidation, Nick Yarrow, the newly appointed group chief executive officer, commented: "Since the enlarged group came together last year, we have been striving to ensure that the best elements of each business have been retained for the benefit of our customers and team members. "This is part of our journey to be more than just a pharmacy - we want to be a trusted source of healthcare services at the heart of each one of the communities we serve".

The current structure of global incentives to develop new antibiotics is insufficient and requires urgent resolution revealed a new report 'Incentivising new antibiotics' by the Office of Health Economics (OHE). OHE analysis demonstrates that on a global level, it is estimated that an effective 10-year incentive would require £3.5bn ($4.2bn) to adequately cover the entire research and development process for a new antibiotic. The report considers how health systems in the UK and around the world can stimulate the research and development (R&D) of new antibiotics. In 2020, the National Institute for Health and Care Excellence (NICE) and NHS England initiated an Antimicrobial Resistance pilot with the aim of incentivising pharmaceutical companies to develop new antibiotics by addressing the issues associated with reimbursement, which historically has deterred companies from pursuing AMR research.

Sources said that, there was peace along the international border in R S Pura and Arnia sectors where Pakistani guns fell silent around 8 pm Thursday.

If you are, ParadiseRO is were you belong. ParadiseRO is a new Ragnarok Online server with a dedicated and experienced Game Master staff.

Lenox Hill Hospital, where Beyonce Knowles gave birth to her baby daughter, has been cleared from complaints. Jeffrey Gordon, a spokesman for the New York State Health Department, said that the complaints patients in a hospital neonatal unit were mistreated during the R&B singer's stay were dismissed by Wednesday, January 11 night.

Heavy duty wheelchairs are also often known as "bariatric" wheelchairs. Any home medical products that have high weight capacities, whether they be wheelchairs, commodes, beds or anything else are more commonly referred to as bariatric products in the recent years. Standard or "off the shelf" heavy duty wheelchairs are wheelchairs which will have a weight capacity of somewhere over 350 lbs. Of course, should the need arise custom wheelchairs can be ordered in cases where even heavier weight capacities are required. Features Aluminum footplates are attractive, crack-proof and lightweight Carbon steel frame with TRIPLE coated chrome for an attractive, chip-proof, maintainable finish Comes standard with carry pocket on back rest Composite Mag-style wheels with chrome hand rim are lightweight and maintenance free Padded armrests provide added patient comfort Precision sealed wheel bearings in front and rear ensure long lasting performance and reliability Heavy duty bariatric wheelchairs for the larger user and the obese. Including extra large self propelled wheelchairs, heavy duty transfer wheelchairs and bariatric transport wheelchairs for the larger or obese user.Heavy duty wheelchairs are made with stronger axles, heavier tubing, double cross braces, gusseted frames and reinforced upholstery to be able to handle the weights required. karma km-8520 Item Code:WCI-29 MRP: R 32085 Our Price:R24063 Net Price:R23582( Apply Coupon Code 'MSW2365' Get 2% Discount ) Availability:Not Available Pin Code:Delivery All Over India (Free Shipping) Warranty:1 Year Seat Widths and Depths Seat widths for heavy duty wheelchairs will range from about 20" to about 30" depending on the model chosen. Seat depths for heavy duty wheelchairs will range from about 18" to about 24" depending on the model chosen. Seat Height Seat heights on a heavy duty wheelchair range between 15" and 22" depe

A wheelchair can help you regain mobility lost due to an injury or chronic health condition. Depending on the size and ability of the user, a lightweight wheelchair or heavy duty wheelchair might be for daily use or as an aid when you need to go a distance farther or longer than you can comfortably walk or stand. Traditional self-propelled wheelchairs have two large rear wheels and a pair of smaller wheels in the front. Advances in design and materials have made different wheelchair models available to suit different needs and body types. Lightweight wheelchairs are easier to maneuver as well as being easier to take on trips, when the wheelchair will be folded and stowed in a car trunk. Wheelchairs of all types typically support up to 250 pounds of body weight. For those with a higher weight, heavy duty wheelchairs, also called bariatric wheelchairs, provide a wider seat for comfort and stronger frame for durability and support. Heavy-duty chairs offer wider seat widths and weight capacity up to 500-lbs. These are folding wheelchairs, shipped assembled ready to use right out of the box.The adaptive equipment is built with a carbon steel frame, extra heavy duty front forks, dual cross bars, reinforced side frame and steel gussets capable of holding up to 700 lbs. The frame has a chrome, chip-proof finish and the upholstery is reinforced making this an easy-to-maintain and durable wheelchair. The mobility aid also comes standard with steel spoke wheels with chrome hand rims, extra large padded armrests for comfort, flat free 8" front casters and push-to-lock wheel locks. Footplates (sold separately). features Extra heavy duty front forks Extra large heavy duty aluminum tapered footplates provide maximum support and are attractive and crack proof (Must be ordered separately) Extra large, contoured plastic armrests provide comfort and support Footrests are tapered for comfort Heavy duty, flat free 8" front casters are adjustable in 2 positions Pow

Lightweight Wheelchair And Lightweight Travel Wheelchair Lightweight travel wheelchair is a Transport Wheelchair that has a lightweight frame and many features that are common on Transporters.Light travel wheelchairs are great for road trips and travel tours, you can go anywhere with a Travel chair, the frame is light and easy to fold and store, this type of wheelchair fits easily into the trunk of your car, or if you are traveling by plane, bus, or train. We provide Lightweight travel wheelchairs that are dependable and easy to carry or fold, our Transport Wheelchair Series includes travel wheelchairs that have many unique features. We also carry the original and upgraded "Airplane Wheelchair", which is specifically used for plane travel, meaning that it was designed to fit in an airplane, through the aisles and through the doors, and through the bridge. Lightweight Travel Wheelchairs are also called "Lightweight Companion Chairs" because they have smaller front wheels, sometimes the rear wheels are the same size as the caster wheels in the front. Companion travel chairs are caregiver propelled, meaning that someone has to push from behind. The lightweight wheelchair market has large variances in prices and quality, which give you many options from which to choose. The Drive Lightweight Transport wheelchair is one of the the lightest transport chairs on the market, weighing in at only 19 lbs! With four great colors to choose from, you can be transported in style. A seat belt and swing-away removable footrests are standard and make it easy to get in and out of this chair. A fold-down back allows for easier storage and transport and padded armrests add additional comfort. Features 8" wheels are maintenance free Easy to fold back for transportation and storage Rear wheel locks for safety Easy to clean nylon upholstery Specification- Selling Price: R 8500 Our Price:R6500 Net Price:R6370 Lightweight Wheelchair Ultra light whee

Global pharmaceutical and biotechnology company AstraZeneca has signed an agreement with Scorpion Therapeutics to discover, develop and commercialize precision medicines against cancer proteins. The collaboration, announced today (January 13), will focus on a class of proteins called transcription factors, which can regulate important cellular processes including cell growth and survival. Many transcription factors have been identified earlier, but were considered 'undruggable' using conventional drug discovery approaches, the company said in a statement. Susan Galbraith, executive vice president, Oncology R&D, AstraZeneca, said: "Unlocking potentially transformative biology is pivotal for delivering the next wave of cancer treatments. "Scorpion's innovative platform is a strong strategic fit as we explore a range of new modalities across our broad drug discovery toolbox with promise to disrupt the activity of these highly-validated cancer targets."

The Royal Pharmaceutical Society has stated that the UK Commission on Pharmacy Professional Leadership lacks the essential transparency, efficiency, and diligence needed for success, urging a shift in its approach. The Commission's operational approach hinders its ability to meet the expectations of both the profession and the public, while prioritising government interests over their needs and preferences, RPS Chief Executive Paul Bennett (R) and President Claire Anderson have jointly said. In a blog post on September 7, the RPS leaders asserted that the Commission lacks transparency and is progressing slowly in implementing proposals that were published seven months ago. "Most pharmacy leaders are growing frustrated and increasingly impatient with the Commission's perceived lack of "meaningful progress" in enhancing leadership within the field," the pair noted. In June 2022, the four UK Chief Pharmaceutical Officers (CPhOs) formed an independent Commission with leadership expertise drawn from various domains, both within and outside of pharmacy, to assess the future of professional leadership. The Pharmacy Minister Neil O'Brien recently revealed that the Commission's costs, funded by the offices of the CPhOs, amounted to £87,745.

The government has launched the Global AMR Innovation Fund (GAMRIF) on Monday (22 May), under which it has announce up to £39 million fund for antimicrobial resistance (AMR) research. Of this new funding package, up to £24 million over four years has been awarded to bolster the UK's partnership with CARB-X - a global AMR research initiative - to support the continued early development of invaluable new antibiotics, vaccines, rapid diagnostics and other products to combat life threatening drug-resistant infections and prevent death and disease across the world. In addition to the CARB-X grant, GAMRIF is investing £5 million over two years into the Global Antibiotic R&D Partnership (GARDP) to develop - and ensure global access to - new antibiotic treatments against major global health priorities. The announcement comes as Health Minister Will Quince attends the World Health Assembly (WHA) in Geneva, Switzerland, and Development Minister Andrew Mitchell participates in an event on health leadership and climate change alongside the WHA. They will announce the launch of the UK government's Global Health Framework for 2023-2025, as part of Minister Quince's address at the WHA. Health Minister Will Quince said: Antimicrobial resistance is a major threat to global health and has led to millions of tragic deaths per year, but the Global AMR Innovation Fund is supporting cutting-edge research and developing vital new treatments to prevent death and disease across the world.

Preet Kaur Gill, Shadow Minister for Primary Care and Public Health, has paid a recent visit to a community pharmacy in Staffordshire to personally experience the services it provides to patients, while staying updated on the latest sector developments. Her visit to Eason's Pharmacy in Tamworth on September 22nd marked her first since assuming new responsibilities for pharmacy policy matters within Labour's health team. Gill was also joined by a member of the National Pharmacy Association staff. The Minister received a comprehensive briefing on Eason's Pharmacy from its third-generation owner, Kieran Eason (R). He outlined the NHS services, which include the New Medicines Service and blood pressure monitoring, and showcased two consultation rooms and an operational dispensary. "It's great that Preet came to learn firsthand about the challenges we face and the substantial potential of community pharmacies nationwide," Eason said. "As an independent prescriber, I have the expertise to provide even more convenient care, but the current funding levels severely limit our contribution."

In a mutual agreement with the STADA board, Roger Scarlett-Smith has stepped down from his role as head of UK. The company has assigned the responsibility of UK operation to Rudolf Bär with current responsibilities as cluster head for Mid-Sized European Markets. Scarlett-Smith joined STADA in October 2018 to lead the UK operation upon the retirement of Dieno George. Prior to this, he had enjoyed an illustrious career in the Consumer Healthcare sector, largely with GlaxoSmithKline, for which he held positions including as President North America, President EMEA and Head of Global Categories. Under his leadership, the STADA UK business has grown sales by 50 per cent and profitability has more than doubled. He has reshaped the business to improve efficiency. There has been a marked acceleration of product innovation including key line extensions to the Zoflora disinfectant range as well as the introduction of a salmeterol and fluticasone inhaler in the Rx respiratory sector. Meanwhile, T+R has developed a fine reputation regionally, being voted number 1 regional company last year and winning many national industry awards.

GlaxoSmithKline on Tuesday (May 31) snapped up US biopharmaceutical firm Affinivax for up to $3.3 billion, expanding further into vaccines before the demerger of its consumer health care arm. The London-listed company has agreed to pay $2.1 billion upfront and up to $1.2 billion in potential development milestones for Affinivax. "GSK plc today announced that it has entered into a definitive agreement to acquire Affinivax, Inc," it said in a statement. "Affinivax is pioneering the development of a novel class of vaccines, the most advanced of which are next-generation pneumococcal vaccines," it added. The Cambridge, Massachusetts-based firm specialises in vaccines for diseases including meningitis, pneumonia and bloodstream infections. "The proposed acquisition further strengthens our vaccines research and development (R&D) pipeline, provides access to a new, potentially disruptive technology, and broadens GSK's existing scientific footprint in the Boston area," said GSK's chief scientific officer Hal Barron.

The Association of the British Pharmaceutical Industry (ABPI) has proposed a Voluntary Scheme for Pricing, Access and Growth (VPAG) that aims to deliver a sustainable approach to medicines provision and maximise the growth potential of the UK life sciences industry. It has published the industry's vision for a new agreement with the government which will deliver for patients, the NHS and the economy. VPAG also includes measures to ensure rapid patient access and adoption of new medicines, as well as opportunities to improve health outcomes and productivity for the whole country. The association's proposals consist of four key areas: restoring an internationally competitive commercial environment for life sciences; supporting UK clinical research and R&D; ensuring rapid patient access and uptake of new medicines; and improving population health and productivity through health innovation. The proposal would deliver over £1bn a year to the NHS - around £300m more than the average delivered under the old scheme before 2023, and comfortably more than the highest contributions ever made before the pandemic.